Omnes Capital et al. invest in Medisse

In addition to the investment, Medisse will receive a credit line from the Dutch Ministry of Economic Affairs supporting innovation and research.

The new investment will back the company's move into the clinical trial stage.

Company
Medisse is an Amersfoort-based pharmaceuticals business, focused on synthetic resorbable soft tissue implants. The company was founded in 2006, when it was spun out of Twente University. Its lead product is FlexiSurge Adhesion Barrier, a patented adhesion prevention film to be used by surgeons.

People
Marius Prins, director, led the deal on behalf of PPM Oost, which is managing IIG's fund. Joost Holthuis represented BioGeneration Ventures. Sandra de Vos is CEO of Medisse.

• Tweet  
• Facebook  
• LinkedIn  
• Google plus  
• Send to  

• Topics
• Benelux
• Healthcare
• Early-stage
• Omnes Capital
• Netherlands